Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.
The dissemination of a malignant neoplasia is a complex process, which requires a set of molecules that remains unknown. It has been suggested that mucins and their carbohydrate-associated antigens may be implicated in tumour spreading which may be also influenced by an anti-MUC1 immune response. In this pilot study, we report the pattern of carbohydrate and peptidic MUC1-associated epitopes on carcinoma cells isolated from bone marrow (BM), taking into account primary tumour histopathologic features. We also bring information about the anti-MUC1 humoral response in these patients. Seventeen patients with invasive breast carcinoma were included. A sample of the primary tumour, a serum sample and a BM aspirate were obtained from each patient. Clinical features studied were tumour size, number of metastatic nodes, histological type and disease stage. Standard immunohistochemistry was performed with antigenic retrieval using different monoclonal antibodies (MAbs): anti carbohydrate antigens: Lewis x (KM380), sLewis x (KM93), Lewis y (C14) and Tn, anti-MUC1 peptide core MAbs: C595, HMFG2 and SM3, anti-cytokeratins, anti-protoncogenes ErbB2 and ErbB3 (IgG) MAbs and also anti-CD34 and anti-CD45 MAbs. ELISA techniques were employed to study circulating MUC1 as well as free and complexed anti-MUC1 antibodies. Immunohistochemical results showed that carbohydrate antigenic expression increases in BM neoplastic cells compared to the original tumours. However, we were not able to demonstrate that a humoral immune response to MUC1 has been induced in these patients. Finally, the employed procedures allow the selective immortalisation of micrometastatic carcinoma cells since short-term cell lines were established.
Croce
M V
MV
Centro de Investigaciones Inmunológicas Básicas y Aplicadas, Facultad de Ciencias Médicas, UNLP La Plata, Argentina.
Isla-Larrain
M
M
Tur
R
R
Rabassa
M E
ME
Segal-Eiras
A
A
D000911:Antibodies, Monoclonal / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000097:blood / Q000276:immunology*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D001853:Bone Marrow / Q000276:immunology*; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology; D044584:Carcinoma, Ductal / Q000276:immunology / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000276:immunology / Q000473:pathology; D018275:Carcinoma, Lobular / Q000276:immunology / Q000473:pathology; D002291:Carcinoma, Papillary / Q000276:immunology / Q000473:pathology; D045744:Cell Line, Tumor; D000939:Epitopes / Q000276:immunology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D018396:Mucin-1 / Q000276:immunology*; D009363:Neoplasm Proteins / Q000276:immunology; D014411:Neoplastic Stem Cells / Q000276:immunology*; D009844:Oligosaccharides / Q000276:immunology; D010455:Peptides / Q000276:immunology; D010865:Pilot Projects
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000939:Epitopes; D018396:Mucin-1; D009363:Neoplasm Proteins; D009844:Oligosaccharides; D010455:Peptides